Therapeutic and adverse effects of three dosages (1, 20 and 100 mg daily) of
flutroline, a new 7-carboline with a predinical pharmacological profile similar to active
neuroleptic agents, were compared in a double-blind clinical trial in 25 newly-admitted
schizophrenic patients. Therapeutic effects and extrapyramidal signs were seen at the 20 and
100-mg daily dosages, but not at the 1-mg dosage. Serum prolactin levels were significantly
elevated only at the 100-mg daily dosage.
A 4-week clinical trial, including a 1-week placebo washout period, assessed
the antipsychotic activity of naltrexone in ‘newly admitted’, actively hallucinating, chronic
schizophrenics. Chronic naltrexone administration was found to benefit 2 patients and
to be of no value in 3 patients. Responsive patients differed from non-responders by the
presence of hallucinations despite adequate neuroleptic maintenance therapy and an appropriate
response to pathological hallucinatory experience. On the basis of these findings, the
possibility of a naltrexone-responsive schizophrenic subgroup was considered.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.